Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PRF Technologies Ltd. (PRFX)
USD1.19
-0.04 (-3.25%)
IL NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
Address
65 Yigal Alon Street 6745442
Tel Aviv, IL
Tel Aviv, IL
CEO
Efraim Cohen-Arazi
Website
prf-tech.com
IPO
2020-09-01
CIK 1801834 ISIN IL0011651580
Description
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.19
-0.04 (-3.25%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
1.05
Float Shares
76.8K
Free Float %
95.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +118.98% | +105.48% | +55.44% | +1.01% | -37.76% | -6.54% | -69.07% | -97.83% | -99.67% | -99.85% | -99.85% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Hold
Price Targets & DCF
Current price
1.19
DCF (Unlevered)
6.43
+439.9%
DCF (Levered)
6.42
+439.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2025-02 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-8.07
Distress
Piotroski F-Score
0 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+99.1% ★ Q4'25: +90.3% (vs Q4'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-25,794.1% Q4'25: -11,617.6% (vs Q4'24)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-29,335.3% Q4'25: -16,200.0% (vs Q4'24)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-96.9% Q4'25: -106.5% (vs Q4'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+3,471.7% Q4'25: +1,380.3% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.01× Q4'25: 0.00× (vs Q4'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
—
est: 12.95M (-100.0%)
|
17.0K
est: 19.31M (-99.9%)
|
10.31M
10.31M – 10.31M
-46.6% YoY
|
11.02M
11.02M – 11.02M
+6.9% YoY
|
37.26M
37.26M – 37.26M
+238.1% YoY
|
| EBITDA |
-14.55M
est: 2.59M (-661.8%)
|
-4.21M
est: 3.86M (-209.1%)
|
2.06M
2.06M – 2.06M
-46.6% YoY
|
2.20M
2.20M – 2.20M
+6.9% YoY
|
7.45M
7.45M – 7.45M
+238.1% YoY
|
| EBIT |
-14.57M
est: 2.59M (-662.4%)
|
-4.99M
est: 3.86M (-229.2%)
|
2.06M
2.06M – 2.06M
-46.6% YoY
|
2.20M
2.20M – 2.20M
+6.9% YoY
|
7.45M
7.45M – 7.45M
+238.1% YoY
|
| Net Income |
-14.59M
est: -255.82M (+94.3%)
|
-4.84M
est: -156.29M (+96.9%)
|
-114.30M
-114.30M – -114.30M
+26.9% YoY
|
-83.98M
-83.98M – -83.98M
+26.5% YoY
|
12.44M
12.44M – 12.44M
+114.8% YoY
|
| SGA |
2.95M
est: 602.37M (-99.5%)
|
3.02M
est: 898.08M (-99.7%)
|
479.42M
479.42M – 479.42M
-46.6% YoY
|
512.68M
512.68M – 512.68M
+6.9% YoY
|
1.73B
1.73B – 1.73B
+238.1% YoY
|
| EPS |
-804.00
est: -394.80 (-103.6%)
|
-7.47
est: -241.20 (+96.9%)
|
-176.40
-176.40 – -176.40
+26.9% YoY
|
-129.60
-129.60 – -129.60
+26.5% YoY
|
19.20
19.20 – 19.20
+114.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-5.96M
OE per share TTM
-90.92
Owner's Yield
-306.60%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
380.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
4
Total invested
31.9K
Insider transactions (90d)
0
Beneficial owners (>5%)
18
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Batsheva Elran | 3.29M | 31.40% | — | 3.29M | — | 3.29M | IN | Israel | 2022-02-11 | ↗ |
| 2 | Ehud Geller | 3.29M | 31.40% | — | 3.29M | — | 3.29M | IN | Israel | 2022-02-11 | ↗ |
| 3 | Medica III Investments (International) L.P. | 3.29M | 31.40% | 3.29M | — | 3.29M | — | PN | Cayman Islands | 2022-02-11 | ↗ |
| 4 | Medica III Investments (Israel) (B) L.P. | 3.29M | 31.40% | 3.29M | — | 3.29M | — | PN | Israel | 2022-02-11 | ↗ |
| 5 | Medica III Investments (Israel) L.P. | 3.29M | 31.40% | 3.29M | — | 3.29M | — | PN | Israel | 2022-02-11 | ↗ |
| 6 | Medica III Investments (P.F.) L.P. | 3.29M | 31.40% | 3.29M | — | 3.29M | — | PN | Israel | 2022-02-11 | ↗ |
| 7 | Medica III Investments (S.F.) L.P. | 3.29M | 31.40% | 3.29M | — | 3.29M | — | PN | Cayman Islands | 2022-02-11 | ↗ |
| 8 | Medica III Management Co. | 3.29M | 31.40% | 3.29M | — | 3.29M | — | PN | Cayman Islands | 2022-02-11 | ↗ |
| 9 | Medica III Management L.P. | 3.29M | 31.40% | 3.29M | — | 3.29M | — | CO | Cayman Islands | 2022-02-11 | ↗ |
| 10 | Poalim Medica III Investments L.P. | 3.29M | 31.40% | 3.29M | — | 3.29M | — | PN | Israel | 2022-02-11 | ↗ |
| 11 | . | 1.75M | 19.70% | 1.75M | — | 1.75M | — | CO | Israel | 2020-11-04 | ↗ |
| 12 | XT Holdings Ltd. | 1.75M | 19.70% | 1.75M | — | 1.75M | — | CO | Israel | 2020-11-04 | ↗ |
| 13 | Armistice Capital Master Fund Ltd. | 661.1K | 7.40% | — | 661.1K | — | 661.1K | CO | Delaware | 2020-09-11 | ↗ |
| 14 | B. Asher | 201.6K | 7.90% | — | 201.6K | — | 193.5K | HC | — | 2024-04-24 | ↗ |
| 15 | Capital LLC | 201.6K | 7.90% | — | 201.6K | — | 193.5K | OO | — | 2024-04-24 | ↗ |
| 16 | P. Kopin | 201.6K | 7.90% | — | 201.6K | — | 193.5K | HC | — | 2024-04-24 | ↗ |
| 17 | Armistice Capital, LLC | 173.0K | 9.99% | — | 173.0K | — | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 18 | Steven Boyd | 173.0K | 9.99% | — | 173.0K | — | — | HC, IN | Delaware | 2024-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
4
+4 vs prev Q
New positions
4
Closed positions
0
Increased
4
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | 13.2K +13.2K (+100.0%) | 26.8K +26.8K (+100.0%) | 2.04% +2.040 pp | 0.00% +0.000 pp | USD2.03 +0.0% | 1 qtrs NEW |
| 2 | MORGAN STANLEY | 1.6K +1.6K (+100.0%) | 3.3K +3.3K (+100.0%) | 0.25% +0.249 pp | 0.00% +0.000 pp | USD2.03 +0.0% | 1 qtrs NEW |
| 3 | UBS GROUP AG | 869.00 +869.0 (+100.0%) | 1.8K +1.8K (+100.0%) | 0.13% +0.134 pp | 0.00% +0.000 pp | USD2.03 +0.0% | 1 qtrs NEW |
| 4 | ADVISOR GROUP HOLDINGS, INC. | 40.00 +40.0 (+100.0%) | 80.00 +80.0 (+100.0%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD2.03 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-18 | Shavit Asaf | Director | — | — | Employee Stock Option (Right to Buy) | 3,000 | 5.55 | 16.7K | 0 | D | ↗ |
| 2026-03-18 | LAWLOR AUGUSTINE | Director | — | — | Employee Stock Option (Right to Buy) | 183 | 30.00 | 5.5K | 0 | D | ↗ |
| 2026-03-18 | GELLER EHUD | Director / Officer | — | — | Employee Stock Option (Right to Buy) | 50 | 5,400.00 | 270.0K | 0 | D | ↗ |
| 2026-03-18 | Cohen-Arazi Efraim | Director / Officer | — | — | Employee Stock Option (Right to Buy)(1)( 2) | 183 | 30.00 | 5.5K | 0 | D | ↗ |
| 2026-03-18 | Broder Eyal | Officer | — | — | Employee Stock Option (Right to Buy) | 180 | 30.00 | 5.4K | 0 | D | ↗ |
| 2026-03-18 | BARON ELLEN S | Director | — | — | Employee Stock Option (Right to Buy) | 50 | 5,400.00 | 270.0K | 0 | D | ↗ |
| 2026-03-18 | Aviel Sigal | Officer | — | — | Employee Stock Option (Right to Buy)(1)( 2) | 104 | 684.00 | 71.1K | 0 | D | ↗ |
Executive team
Top executives
EBIT / Employee
-24.9K
Shares Outstanding
80.5K
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Eyal Broder | Chief Financial Officer | 353.0K | male |
| Sigal Aviel | Chief Operating Officer | 341.0K | — |
| Ehud Geller | Executive Chairman | 297.0K | — |
| Rita Keynan | Vice President of Pharmaceutical Operations | 287.0K | female |
| Efraim Cohen-Arazi | Interim CEO & Director | — | male |
| Stephen A. Cooper | Executive Vice President of Development | — | — |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PRFX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
